Daranide (Dichlorphenamide) - Summary

DARANIDE SUMMARY

DARANIDE (Dichlorphenamide) is an oral carbonic anhydrase inhibitor.

For adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

See all indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Daranide (Dichlorphenamide)

Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. [2000.01]
Although the carbonic anhydrase inhibitors have been used in the treatment of the primary periodic paralyses (PPs), their efficacy has not been demonstrated in double-blind, placebo-controlled trials. Therefore, we tested the efficacy of dichlorphenamide (DCP; Daranide), a potent carbonic anhydrase inhibitor, in the treatment of episodic weakness in the primary PPs...

more studies >>

Clinical Trials Related to Daranide (Dichlorphenamide)

Hyper- and Hypokalemic Periodic Paralysis Study [Recruiting]
The purpose of this study is to determine which drug, acetazolamide or dichlorphenamide is better for treating periodic paralysis and for improving strength.

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders [Completed]
OBJECTIVES:

I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis.

more trials >>